These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37744743)

  • 1. Is the Neuroimmune System a Therapeutic Target for Opioid Use Disorder? A Systematic Review.
    Toloff K; Woodcock EA
    Med Res Arch; 2022 Aug; 10(8):. PubMed ID: 37744743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimmune Mechanisms of Opioid Use Disorder and Recovery: Translatability to Human Studies, and Future Research Directions.
    Butelman ER; Goldstein RZ; Nwaneshiudu CA; Girdhar K; Roussos P; Russo SJ; Alia-Klein N
    Neuroscience; 2023 Sep; 528():102-116. PubMed ID: 37562536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial neuroimmune signaling in opioid reward.
    Zhang H; Largent-Milnes TM; Vanderah TW
    Brain Res Bull; 2020 Feb; 155():102-111. PubMed ID: 31790721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder.
    Lee YK; Gold MS; Fuehrlein BS
    J Neurol Sci; 2022 Jan; 432():120094. PubMed ID: 34933249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the Dynamics of Heroin and Illicit Opioid Use Disorder, Treatment, and Recovery.
    Cole S; Wirkus S
    Bull Math Biol; 2022 Mar; 84(4):48. PubMed ID: 35237877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid use disorder: current trends and potential treatments.
    Lee YK; Gold MS; Blum K; Thanos PK; Hanna C; Fuehrlein BS
    Front Public Health; 2023; 11():1274719. PubMed ID: 38332941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Evidence for Cannabis' Role in Opioid Use Disorder.
    Wiese B; Wilson-Poe AR
    Cannabis Cannabinoid Res; 2018; 3(1):179-189. PubMed ID: 30221197
    [No Abstract]   [Full Text] [Related]  

  • 8. Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.
    Leyrer-Jackson JM; Acuña AM; Olive MF
    Expert Opin Pharmacother; 2022 Nov; 23(16):1819-1830. PubMed ID: 36278879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.
    Pergolizzi JV; Raffa RB; Rosenblatt MH
    J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamics of heroin and illicit opioid use disorder, casual use, treatment, and recovery: A mathematical modeling analysis.
    Cole S; Olive MF; Wirkus S
    Math Biosci Eng; 2024 Feb; 21(2):3165-3206. PubMed ID: 38454724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders.
    Onisiforou A; Michael A; Apostolakis M; Mammadov E; Mitka A; Kalatta MA; Koumas M; Georgiou A; Chatzittofis A; Panayiotou G; Georgiou P; Zarate CA; Zanos P
    Biol Psychiatry; 2024 Sep; ():. PubMed ID: 39293647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an Emergency Department-Based Intervention to Expand Access to Medications for Opioid Use Disorder in a Medicaid Nonexpansion Setting: Protocol for Engagement and Community Collaboration.
    Walter LA; Li L; Rodgers JB; Hess JJ; Skains RM; Delaney MC; Booth J; Hess EP
    JMIR Res Protoc; 2021 Apr; 10(4):e18734. PubMed ID: 33913818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice.
    El Jordi O; Fischer KD; Meyer TB; Atwood BK; Oblak AL; Pan RW; McKinzie DL
    Adv Drug Alcohol Res; 2022; 2():10848. PubMed ID: 38390615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic profiles associated with opioid use and opioid use disorder: a narrative review of the literature.
    Byanyima JI; Li X; Vesslee SA; Kranzler HR; Shi Z; Wiers CE
    Curr Addict Rep; 2023 Sep; 10(3):581-593. PubMed ID: 37982033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adolescent opioid abuse: Role of glial and neuroimmune mechanisms.
    Rahman S; Rahman ZI; Ronan PJ; Lutfy K; Bell RL
    Int Rev Neurobiol; 2022; 161():147-165. PubMed ID: 34801168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report.
    Bart GB; Saxon A; Fiellin DA; McNeely J; Muench JP; Shanahan CW; Huntley K; Gore-Langton RE
    Addict Sci Clin Pract; 2020 Jan; 15(1):4. PubMed ID: 31948487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
    Chalhoub RM; Kalivas PW
    Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
    Gold MS; Baron D; Bowirrat A; Blum K
    J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research.
    Moningka H; Lichenstein S; Worhunsky PD; DeVito EE; Scheinost D; Yip SW
    Neuropsychopharmacology; 2019 Jan; 44(2):259-273. PubMed ID: 30283002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.